𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HPV 16 E7 antibody levels in cervical cancer patients: Before and after treatment

✍ Scribed by Di Lonardo, Anna; Marcante, Maria Luisa; Poggiali, Federica; Venuti, Aldo

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
229 KB
Volume
54
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Antibody response to HPV16 E7 oncoprotein may represent a marker of cervical cancer. A HPV16 GST-E7 fusion protein was used in a Western Blot assay to analyse the HPV16 E7 antibody response in 30 patients before and after treatment for cervical carcinoma (stage IIB or IIIB). Patients were treated with three courses of cisplatin/bleomycin therapy followed by surgery, or with surgery alone. Thirteen out of 30 patients had serum antibodies to HPV16 E7 antigen. Three months after chemotherapy little or no change in antibody titre was detected. In contrast, after surgery, a significant decrease in antibody titre was observed in 9/10 patients. In two cases the titre declined to zero 3 and 9 months after treatment, respectively. These results confirm the usefulness of studying anti-HPV16 E7 antibody profile in cervical cancer patients and suggest that the serum response correlates with tumour burden.

πŸ“œ SIMILAR VOLUMES

Uniform distribution of HPV 16 E6 and E7
Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer
✍ Ingo Nindl; Knuth Rindfleisch; Beatrix Lotz; Achim Schneider; Matthias DΓΌrst πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 160 KB πŸ‘ 2 views

High-risk human papillomaviruses (HPV), particularly HPV 16, are associated with invasive cervical cancer (ICC), and persistent high-risk HPV infection is considered to be a marker for progressive cervical intra-epithelial neoplasia (CIN). However, most high-risk, HPV-infected, pre-cancerous lesions

Characterization of humoral immune respo
Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers
✍ Miriam Reuschenbach; Tim Waterboer; Keng-Ling Wallin; Jens Einenkel; Joakim Dill πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 French βš– 241 KB πŸ‘ 1 views

## Abstract The cellular tumor suppressor p16 is strongly overexpressed in cervical cancers and precancers. We have previously demonstrated that infiltrating T lymphocytes reactive against p16 can be found in cervical cancer patients. Here, we analyzed whether p16 induces humoral immune responses.

Detection of HPV 16 and HPV 18 DNA in th
Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer
✍ Patti Kay; Bruce Allan; Lynette Denny; Margaret Hoffman; Anna-Lise Williamson πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix. A few studies have reported the presence of HPV DNA in the blood of women with cervical neoplasia. The aim of this study was to determine if HPV DNA could be detec

Analysis of mutations in the URR and E6/
Analysis of mutations in the URR and E6/E7 oncogenes of HPV 16 cervical cancer isolates from central China
✍ Amanda L. Stephen; Carol H. Thompson; Martin H. Tattersall; Yvonne E. Cossart; B πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 82 KB πŸ‘ 2 views

High rates of cervical cancer have been reported from parts of China and this may reflect a predominance of cervical infection with particularly aggressive human papillomavirus (HPV) variants. This PCR-based investigation of cervical tumours from Sichuan province in central China demonstrated an HPV